Physician profile
William Carr Mcbee
NPI 1891997979
$17,227.04
in general payments reported to CMS, 2019-2025
21 companies · $603 in 2025
The $603 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,992 · 2020: $2,625 · 2021: $86.41 · 2022: $252 · 2023: $5,792 · 2024: $877 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,000 · Food and Beverage: $2,409 · Travel and Lodging: $775 · Education: $87.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,000.00 |
| Food and Beverage | $2,409.01 |
| Travel and Lodging | $774.67 |
| Education | $87.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biom'Up Sa | $6,871.84 | 2019 | |
| Dilon Technologies, INC. | $4,614.64 | 2023-2025 | Hemoblast Bellows |
| Abbvie INC. | $2,625.00 | 2020 | |
| Intuitive Surgical, INC. | $938.27 | 2019-2023 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals Lp | $520.18 | 2021-2025 | Lynparza |
| Eisai INC. | $468.67 | 2023-2025 | |
| Glaxosmithkline, LLC. | $310.32 | 2023-2025 | Zejula, Jemperli |
| Merck Sharp & Dohme LLC | $166.91 | 2022-2025 | Keytruda, Lynparza |
| Seagen INC. | $117.82 | 2022-2023 | Tivdak |
| Tempus Ai, INC | $106.68 | 2024 | |
| Kerecis Limited | $100.20 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Covidien Lp | $80.35 | 2019 | |
| Kci USA, INC. | $70.20 | 2023 | Prevena |
| Pfizer INC. | $63.89 | 2024-2025 | |
| Caris Mpi, INC. | $62.02 | 2025 | Mi Cancer Seek |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $22.21 | 2022 | |
| Medtronic, INC. | $21.48 | 2022 | |
| Angiodynamics, INC. | $19.11 | 2022 | |
| Myovant Sciences INC. | $16.35 | 2021 | |
| Ethicon US, LLC | $16.22 | 2022 | |
| Stryker Corporation | $14.68 | 2023 | S-Series |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mcbee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.